Author(s) :
Cristina Lungulescu1, Ștefan Răileanu2, Ștefania Dumitru2, Mihaela Dănciulescu3
1 University of Medicine and Pharmacy of Craiova, Doctoral School, Craiova, Romania
2 Department of Oncology, Filantropia Clinical Hospital, Craiova, Romania
3 University of Medicine and Pharmacy of Craiova, Department of Oncology, Craiova, Romania
Corresponding author: Cristina Lungulescu, Email: cristina.lungulescu@yahoo.com
Publication History: Received - , Revised - , Accepted - , Published Online - .
Copyright: © The author(s). Published by Casa Cărții de Știință.
User License: Creative Commons Attribution – NonCommercial (CC BY-NC)
PDF
Share
Abstract
Prostate cancer is the second most frequent malignancy worldwide, with an increased incidence over the last two decades. Most patients are asymptomatic at diagnosis due to widespread opportunistic prostate-specific antigen-based screening. Cerebral metastases originating from prostatic tumors are rare, occurring in 0.16% to 0.63% of prostate cancer cases, and generally developing in the setting of widespread disease. We report the case of a 62-year-old male with symptomatic isolated brain metastasis as an early clinical presentation of prostate adenocarcinoma in the setting of a normal PSA and digital rectal examination.
Next-generation sequencing panel revealed a mutation in the PALB2 gene. Germline mutation in genes involved in homologous recombination repair complex, such as BRCA1, BRCA2, and PALB2 increase the incidence and the aggressiveness of multiple cancer types including prostate cancer, yet can provide alternative treatment options using PARP inhibitors after disease progression for patients previously treated with enzalutamide or abiraterone.
